Low frequency of CYP2D6 poor metabolizers among schizophrenia patients

Pharmacogenomics Journal

Volumn 7, Issue 6, 2007, Pages 408-410

  LLerena, A ^a,b   Dorado, P ^a   Penas LLedo E M ^a   Caceres M C ^a   De la Rubia, A ^c  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b HOSPITAL INFANTA CRISTINA   (Spain)

^c Hospital de Merida   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6;

ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SPAIN;

CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; MALE; PHENOTYPE; POLYMORPHISM, GENETIC; RISK FACTORS; SCHIZOPHRENIA; SPAIN;

EID: 36549047439     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500439     Document Type: Article

References (23)

1. LLerena A, Cobaleda J, Martinez C, Benitez J. Interethnic differences in drug metabolism: Influence of genetic, environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet 1996; 21: 129-138.
2. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: Useful aid to prescribing? Clin Pharmacokinet 2002; 41: 453-470.
3. LLerena A, Berecz R, de la Rubia 4, Fernandez-Salguero P, Dorado P. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2136 genotypes. Ther Drug Monit 2001; 23: 616-620.
4. LLerena A, Berecz R, de la Rubia A, Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity, plasma concentration of thioridazine in patients. J Psychopharmacol 2002; 16: 361-364.
5. LLerena A, Berecz R, Dorado P, de la Rubia A. QTc interval, CYP2D6, CYP2C9 genotypes, risperidone plasma concentrations. J Psychopharmacol 2004; 18: 189-193.
6. LLerena A, de la Rubia A, Berecz R, Dorado P. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2136, CYP2C9 genotypes in psychiatric patients. Pharmacopsychiatry 2004; 37: 69-73.
7. Berecz R, de la Rubia A, Dorado P, Fernandez-Salguero P, Dahl ML, LLerena A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking, CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 2003; 59: 45-50.
8. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M. Cellular localization, regional distribution of CYP2D6 mRNA, protein expression in human brain. Pharmacogenetics 2001; 11: 237-245.
9. Miksys 5, Rao Y, Hoffmann E, Mash DC, Tyndale RF. Regional, cellular expression of CYP2D6 in human brain: Higher levels in alcoholics. J Neurochem 2002; 82: 1376-1387.
10. LLerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L. Relationship between personality, debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psych Scand 1993; 87: 23-28.
11. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans, their descendants. Pharmacogenomics 2002; 3: 229-243.
12. Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for clebrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452-459.
13. Dawson E, Powell JF, Nothen MM, Crocq MA, Lanczik M, Komer J et al. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia. Psychiatr Genet 1994; 4: 215-218.
14. Daniels J, Williams J, Asherson P, McGuffin P, Owen M. No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the cloparnine transporter (DAT). Am J Med Genet 1995; 60: 85-87.
15. Pirmohamed M, Wild MJ, Kitteringham NR, O'Brien K, Buchan IE, Back DJ et al. Lack association between schizophrenia and the CYP2D6 gene polymorphisms. Am J Med Genet 1996; 67: 236-237.
16. Jonsson EG, Dahl ML, Roh HK, Jerling M, Sedvall GC. Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia. Psychiatr Genet 1998; 8: 25-28.
17. Chen CH, Hung CC, Wei FC, Koong FJ. Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan. Psychiatr Genet 2001; 11: 153-155.
18. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438-452.
19. Dahl AA, Løwert A, Asserson S, Bjarking L, Berglund J, Kristensen F et al. Hydroxylation polymorphism of debrisoquine hydroxylase (CYP2D6) in patients with schizophrenia in Norway and Denmark. Hum Psychopharmacol 1998; 13: 509-511.
20. Dorado P, Caceres MC, Pozo-Guisado E, Wong ML, Licinio J, Llerena A. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 2005; 39: 571-574.
21. Hiroi T, Imaoka S, Funae Y. Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1998; 249: 838-843.
22. Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13: 173-181.
23. Niwa T, Hiroi T, Tsuzuki D, Yamamoto S, Narimatsu S. Effect of genetic polymorphism on the metabolism of enclogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res 2004; 129: 117-123.